Emerging anti‐HDV drugs and HBV cure strategies with anti‐HDV activity
Hepatitis delta virus (HDV) is a satellite RNA virus that requires the presence of hepatitis B virus (HBV) for its replication. HDV/HBV co‐infection is often associated with a faster disease progression of chronic hepatitis in comparison to HBV mono‐infection. Therefore, the development of novel ant...
Gespeichert in:
| Veröffentlicht in: | Liver international 2023-08, Vol.43 (S1), p.87-95 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 95 |
|---|---|
| container_issue | S1 |
| container_start_page | 87 |
| container_title | Liver international |
| container_volume | 43 |
| creator | Roca Suarez, Armando A. Batbold, Enkhtuul Bartosch, Birke Dashdorj, Naranjargal Testoni, Barbara Zoulim, Fabien |
| description | Hepatitis delta virus (HDV) is a satellite RNA virus that requires the presence of hepatitis B virus (HBV) for its replication. HDV/HBV co‐infection is often associated with a faster disease progression of chronic hepatitis in comparison to HBV mono‐infection. Therefore, the development of novel antiviral therapies targeting HDV represents a high priority and an urgent medical need. In this review, we summarize the ongoing efforts to evaluate promising HDV‐specific drugs, such as lonafarnib (LNF), pegylated interferon lambda (PEG‐IFN‐λ) and their use as a combination therapy. Furthermore, we review the most recent developments in the area of anti‐HBV drugs with potential effects against HDV, including therapeutic agents targeting hepatitis B surface antigen (HBsAg) expression, secretion and function. Finally, we consider the important insights that have emerged from the development of these potential antiviral strategies, as well as the intriguing questions that remain to be elucidated in this rapidly changing field. |
| doi_str_mv | 10.1111/liv.15417 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2796162843</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2796162843</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3537-2e9ff7b9c1997a60c5e15831918fa2ff0da074eced27ef79998345d8daa9b47e3</originalsourceid><addsrcrecordid>eNp10EFLwzAUB_AgipvTg19ACl700C1pmqY56pxuMvCiu4asfa0ZbTeTdmM3P4Kf0U9itFNE8F3yCD_-PP4InRLcJ24GhV73CQsJ30NdEvLYpwEl-z97QDvoyNoFxkQIRg5Rh3JMOI5wF92PSjC5rnJPVbV-f30b38y81DS5dR-pN76eeUljwLO1UTXkGqy30fXzb62SWq91vT1GB5kqLJzs3h56uh09Dsf-9OFuMrya-glllPsBiCzjc5G4Y7iKcMKAsJgSQeJMBVmGU4V5CAmkAYeMCyFiGrI0TpUS85AD7aGLNndlli8N2FqW2iZQFKqCZWNlwEVEoiAOqaPnf-hi2ZjKXSeDmIkYMxxGTl22KjFLaw1kcmV0qcxWEiw_C5auYPlVsLNnu8RmXkL6I78bdWDQgo0uYPt_kpxOZm3kB3HQhNo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2859805046</pqid></control><display><type>article</type><title>Emerging anti‐HDV drugs and HBV cure strategies with anti‐HDV activity</title><source>Access via Wiley Online Library</source><creator>Roca Suarez, Armando A. ; Batbold, Enkhtuul ; Bartosch, Birke ; Dashdorj, Naranjargal ; Testoni, Barbara ; Zoulim, Fabien</creator><creatorcontrib>Roca Suarez, Armando A. ; Batbold, Enkhtuul ; Bartosch, Birke ; Dashdorj, Naranjargal ; Testoni, Barbara ; Zoulim, Fabien</creatorcontrib><description>Hepatitis delta virus (HDV) is a satellite RNA virus that requires the presence of hepatitis B virus (HBV) for its replication. HDV/HBV co‐infection is often associated with a faster disease progression of chronic hepatitis in comparison to HBV mono‐infection. Therefore, the development of novel antiviral therapies targeting HDV represents a high priority and an urgent medical need. In this review, we summarize the ongoing efforts to evaluate promising HDV‐specific drugs, such as lonafarnib (LNF), pegylated interferon lambda (PEG‐IFN‐λ) and their use as a combination therapy. Furthermore, we review the most recent developments in the area of anti‐HBV drugs with potential effects against HDV, including therapeutic agents targeting hepatitis B surface antigen (HBsAg) expression, secretion and function. Finally, we consider the important insights that have emerged from the development of these potential antiviral strategies, as well as the intriguing questions that remain to be elucidated in this rapidly changing field.</description><identifier>ISSN: 1478-3223</identifier><identifier>EISSN: 1478-3231</identifier><identifier>DOI: 10.1111/liv.15417</identifier><identifier>PMID: 37017060</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Antigens ; Antiviral agents ; antivirals ; Chronic infection ; combination therapy ; Drug development ; Drugs ; HBsAg ; HBV ; HDV ; Hepatitis ; Hepatitis B ; Hepatitis B surface antigen ; Interferon ; Pharmacology ; RNA viruses ; Satellite RNA ; Viruses</subject><ispartof>Liver international, 2023-08, Vol.43 (S1), p.87-95</ispartof><rights>2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.</rights><rights>2023 John Wiley & Sons A/S</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3537-2e9ff7b9c1997a60c5e15831918fa2ff0da074eced27ef79998345d8daa9b47e3</citedby><cites>FETCH-LOGICAL-c3537-2e9ff7b9c1997a60c5e15831918fa2ff0da074eced27ef79998345d8daa9b47e3</cites><orcidid>0000-0001-5588-5465 ; 0000-0002-2245-0083</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fliv.15417$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fliv.15417$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37017060$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Roca Suarez, Armando A.</creatorcontrib><creatorcontrib>Batbold, Enkhtuul</creatorcontrib><creatorcontrib>Bartosch, Birke</creatorcontrib><creatorcontrib>Dashdorj, Naranjargal</creatorcontrib><creatorcontrib>Testoni, Barbara</creatorcontrib><creatorcontrib>Zoulim, Fabien</creatorcontrib><title>Emerging anti‐HDV drugs and HBV cure strategies with anti‐HDV activity</title><title>Liver international</title><addtitle>Liver Int</addtitle><description>Hepatitis delta virus (HDV) is a satellite RNA virus that requires the presence of hepatitis B virus (HBV) for its replication. HDV/HBV co‐infection is often associated with a faster disease progression of chronic hepatitis in comparison to HBV mono‐infection. Therefore, the development of novel antiviral therapies targeting HDV represents a high priority and an urgent medical need. In this review, we summarize the ongoing efforts to evaluate promising HDV‐specific drugs, such as lonafarnib (LNF), pegylated interferon lambda (PEG‐IFN‐λ) and their use as a combination therapy. Furthermore, we review the most recent developments in the area of anti‐HBV drugs with potential effects against HDV, including therapeutic agents targeting hepatitis B surface antigen (HBsAg) expression, secretion and function. Finally, we consider the important insights that have emerged from the development of these potential antiviral strategies, as well as the intriguing questions that remain to be elucidated in this rapidly changing field.</description><subject>Antigens</subject><subject>Antiviral agents</subject><subject>antivirals</subject><subject>Chronic infection</subject><subject>combination therapy</subject><subject>Drug development</subject><subject>Drugs</subject><subject>HBsAg</subject><subject>HBV</subject><subject>HDV</subject><subject>Hepatitis</subject><subject>Hepatitis B</subject><subject>Hepatitis B surface antigen</subject><subject>Interferon</subject><subject>Pharmacology</subject><subject>RNA viruses</subject><subject>Satellite RNA</subject><subject>Viruses</subject><issn>1478-3223</issn><issn>1478-3231</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp10EFLwzAUB_AgipvTg19ACl700C1pmqY56pxuMvCiu4asfa0ZbTeTdmM3P4Kf0U9itFNE8F3yCD_-PP4InRLcJ24GhV73CQsJ30NdEvLYpwEl-z97QDvoyNoFxkQIRg5Rh3JMOI5wF92PSjC5rnJPVbV-f30b38y81DS5dR-pN76eeUljwLO1UTXkGqy30fXzb62SWq91vT1GB5kqLJzs3h56uh09Dsf-9OFuMrya-glllPsBiCzjc5G4Y7iKcMKAsJgSQeJMBVmGU4V5CAmkAYeMCyFiGrI0TpUS85AD7aGLNndlli8N2FqW2iZQFKqCZWNlwEVEoiAOqaPnf-hi2ZjKXSeDmIkYMxxGTl22KjFLaw1kcmV0qcxWEiw_C5auYPlVsLNnu8RmXkL6I78bdWDQgo0uYPt_kpxOZm3kB3HQhNo</recordid><startdate>202308</startdate><enddate>202308</enddate><creator>Roca Suarez, Armando A.</creator><creator>Batbold, Enkhtuul</creator><creator>Bartosch, Birke</creator><creator>Dashdorj, Naranjargal</creator><creator>Testoni, Barbara</creator><creator>Zoulim, Fabien</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7T5</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-5588-5465</orcidid><orcidid>https://orcid.org/0000-0002-2245-0083</orcidid></search><sort><creationdate>202308</creationdate><title>Emerging anti‐HDV drugs and HBV cure strategies with anti‐HDV activity</title><author>Roca Suarez, Armando A. ; Batbold, Enkhtuul ; Bartosch, Birke ; Dashdorj, Naranjargal ; Testoni, Barbara ; Zoulim, Fabien</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3537-2e9ff7b9c1997a60c5e15831918fa2ff0da074eced27ef79998345d8daa9b47e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Antigens</topic><topic>Antiviral agents</topic><topic>antivirals</topic><topic>Chronic infection</topic><topic>combination therapy</topic><topic>Drug development</topic><topic>Drugs</topic><topic>HBsAg</topic><topic>HBV</topic><topic>HDV</topic><topic>Hepatitis</topic><topic>Hepatitis B</topic><topic>Hepatitis B surface antigen</topic><topic>Interferon</topic><topic>Pharmacology</topic><topic>RNA viruses</topic><topic>Satellite RNA</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Roca Suarez, Armando A.</creatorcontrib><creatorcontrib>Batbold, Enkhtuul</creatorcontrib><creatorcontrib>Bartosch, Birke</creatorcontrib><creatorcontrib>Dashdorj, Naranjargal</creatorcontrib><creatorcontrib>Testoni, Barbara</creatorcontrib><creatorcontrib>Zoulim, Fabien</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Liver international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Roca Suarez, Armando A.</au><au>Batbold, Enkhtuul</au><au>Bartosch, Birke</au><au>Dashdorj, Naranjargal</au><au>Testoni, Barbara</au><au>Zoulim, Fabien</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Emerging anti‐HDV drugs and HBV cure strategies with anti‐HDV activity</atitle><jtitle>Liver international</jtitle><addtitle>Liver Int</addtitle><date>2023-08</date><risdate>2023</risdate><volume>43</volume><issue>S1</issue><spage>87</spage><epage>95</epage><pages>87-95</pages><issn>1478-3223</issn><eissn>1478-3231</eissn><abstract>Hepatitis delta virus (HDV) is a satellite RNA virus that requires the presence of hepatitis B virus (HBV) for its replication. HDV/HBV co‐infection is often associated with a faster disease progression of chronic hepatitis in comparison to HBV mono‐infection. Therefore, the development of novel antiviral therapies targeting HDV represents a high priority and an urgent medical need. In this review, we summarize the ongoing efforts to evaluate promising HDV‐specific drugs, such as lonafarnib (LNF), pegylated interferon lambda (PEG‐IFN‐λ) and their use as a combination therapy. Furthermore, we review the most recent developments in the area of anti‐HBV drugs with potential effects against HDV, including therapeutic agents targeting hepatitis B surface antigen (HBsAg) expression, secretion and function. Finally, we consider the important insights that have emerged from the development of these potential antiviral strategies, as well as the intriguing questions that remain to be elucidated in this rapidly changing field.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>37017060</pmid><doi>10.1111/liv.15417</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-5588-5465</orcidid><orcidid>https://orcid.org/0000-0002-2245-0083</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1478-3223 |
| ispartof | Liver international, 2023-08, Vol.43 (S1), p.87-95 |
| issn | 1478-3223 1478-3231 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2796162843 |
| source | Access via Wiley Online Library |
| subjects | Antigens Antiviral agents antivirals Chronic infection combination therapy Drug development Drugs HBsAg HBV HDV Hepatitis Hepatitis B Hepatitis B surface antigen Interferon Pharmacology RNA viruses Satellite RNA Viruses |
| title | Emerging anti‐HDV drugs and HBV cure strategies with anti‐HDV activity |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T02%3A07%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Emerging%20anti%E2%80%90HDV%20drugs%20and%20HBV%20cure%20strategies%20with%20anti%E2%80%90HDV%20activity&rft.jtitle=Liver%20international&rft.au=Roca%20Suarez,%20Armando%20A.&rft.date=2023-08&rft.volume=43&rft.issue=S1&rft.spage=87&rft.epage=95&rft.pages=87-95&rft.issn=1478-3223&rft.eissn=1478-3231&rft_id=info:doi/10.1111/liv.15417&rft_dat=%3Cproquest_cross%3E2796162843%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2859805046&rft_id=info:pmid/37017060&rfr_iscdi=true |